In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

Pseudomonas aeruginosa is an opportunistic pathogen that is a leading cause of morbidity
and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of …

For around three decades, the fluoroquinolone (FQ) antibiotic ciprofloxacin has been used
to treat a range of diseases, including chronic otorrhea, endocarditis, lower respiratory tract …

P. aeruginosa is classified as a priority one pathogen by the World Health Organisation, and
new drugs are urgently needed, due to the emergence of multidrug-resistant (MDR) strains …

Antibiotics are powerful drugs used in the treatment of bacterial infections. The inappropriate
use of these medicines has driven the dissemination of antibiotic resistance (AR) in most …

The global emergence of multidrug-resistant Gram-negative bacteria is a growing threat to
antibiotic therapy. The chromosomally encoded drug efflux mechanisms that are ubiquitous …

The increasing prevalence of chronic and hospital-acquired infections produced by
multidrug-resistant (MDR) or extensively drug-resistant (XDR) Pseudomonas aeruginosa …

The antibiotic ciprofloxacin is used extensively to treat a wide range of infections caused by
the opportunistic pathogen Pseudomonas aeruginosa. Due to its extensive use, the …

The evolution of antibiotic resistance carries a fitness cost, expressed in terms of reduced
competitive ability in the absence of antibiotics. This cost plays a key role in the dynamics of …

The rise of antibiotic resistance in many bacterial pathogens has been driven by the spread
of a few successful strains, suggesting that some bacteria are genetically pre-disposed to …